Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | GYS1 | P13807 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17428307 | 0.81 | SCN9A (0.59) | L3MBTL1ALDH1A1NPSR1LOXL2GYS1 | |
| SCHEMBL19064772 | 0.81 | SCN9A (0.59) | L3MBTL1ALDH1A1NPSR1LOXL2GYS1 | |
| SCHEMBL17428497 | 0.79 | SCN9A (0.48) | L3MBTL1ALDH1A1NPSR1LOXL2GYS1 | |
| SCHEMBL21075496 | 0.77 | SCN9A (0.46) | L3MBTL1ALDH1A1NPSR1LOXL2GYS1 | |
| SCHEMBL19389012 | 0.76 | SCN9A (0.64) | SCN9A | |
| SCHEMBL20307085 | 0.75 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1NPSR1GYS1SCN9A | |
| SCHEMBL19083706 | 0.73 | SCN9A (0.46) | SCN9A | |
| SCHEMBL20307084 | 0.71 | SCN9A (0.48) | SCN9A | |
| SCHEMBL21075202 | 0.71 | SCN9A (0.55) | ALDH1A1SCN9A | |
| SCHEMBL17427703 | 0.71 | SCN9A (0.55) | ALDH1A1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | L3MBTL1 3827/4885ALDH1A1 1155/4885NPSR1 367/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | L3MBTL1 3827/4885ALDH1A1 1155/4885NPSR1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.